Claims
- 1. A method for down regulating expression of vascular endothelial growth factor receptors (VEGFRs) in a cell comprising contacting the cell with a nucleic acid molecule that down regulates expression of VEGFR1 and a nucleic acid molecule that down regulates expression of VEGFR2 under conditions suitable for down regulating expression of VEGFRs in the cell.
- 2. The method of claim 1, wherein the nucleic acid molecule that down regulates expression of VEGFR1 and the nucleic acid molecule that down regulates expression of VEGFR2 are enzymatic nucleic acid molecules.
- 3. The method of claim 1, wherein the nucleic acid molecule that down regulates expression of VEGFR1 and the nucleic acid molecule that down regulates expression of VEGFR2 are short interfering nucleic acid molecules.
- 4. The method of claim 1, wherein the nucleic acid molecule that down regulates expression of VEGFR1 and the nucleic acid molecule that down regulates expression of VEGFR2 are antisense nucleic acid molecules.
- 5. The method of claim 1, wherein the nucleic acid molecule that down regulates expression of VEGFR1 or VEGFR2 is selected from the group consisting of an enzmatic nucleic acid molecule, an antisense nucleic acid molecule, and a short interfering nucleic acid molecule.
- 6. The method of claim 1, wherein said cell is a mammalian cell.
- 7. The method of claim 1, wherein said cell is a human cell.
- 8. The method of claim 1, wherein one or both of the nucleic acid molecules contact the cell in the presence of a delivery reagent.
- 9. The method of claim 8, wherein said delivery reagent is a lipid.
- 10. The method of claim 9, wherein said lipid is a cationic lipid.
- 11. The method of claim 8, wherein said delivery reagent is a liposome.
- 12. A method for treating cancer in a subject comprising administering to the subject a nucleic acid molecule that down regulates expression of VEGFR1 and a nucleic acid molecule that down regulates expression of VEGFR2 under conditions suitable for the treatment.
- 13. The method of claim 12, wherein the nucleic acid molecule that down regulates expression of VEGFR1 and the nucleic acid molecule that down regulates expression of VEGFR2 are enzymatic nucleic acid molecules.
- 14. The method of claim 12, wherein the nucleic acid molecule that down regulates expression of VEGFR1 and the nucleic acid molecule that down regulates expression of VEGFR2 are short interfering nucleic acid molecules.
- 15. The method of claim 12, wherein the nucleic acid molecule that down regulates expression of VEGFR1 and the nucleic acid molecule that down regulates expression of VEGFR2 are antisense nucleic acid molecules.
- 16. The method of claim 12, wherein the nucleic acid molecule that down regulates expression of VEGFR1 or VEGFR2 is selected from the group consisting of an enzmatic nucleic acid molecule, an antisense nucleic acid molecule, and a short interfering nucleic acid molecule.
- 17. The method of claim 12, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, colorectal cancer, and melanoma.
- 18. The method of claim 12, further comprising the administration of one or more therapies under conditions suitable for the treatment.
- 19. The method of claim 12, wherein said administration is in the presence of a delivery reagent.
- 20. The method of claim 19, wherein said delivery reagent is a lipidcationic lipid, phospholipid, or liposome.
- 21. A method for treating cancer in a subject comprising administering to the subject a nucleic acid molecule that down regulates expression of a VEGF receptor in combination with interferon under conditions suitable for the treatment.
- 22. The method of claim 21, wherein the nucleic acid molecule that down regulates expression of a VEGF receptor is an enzymatic nucleic acid molecule.
- 23. The method of claim 21, wherein the nucleic acid molecule that down regulates expression of a VEGF receptor is an antisense acid molecule.
- 24. The method of claim 21, wherein the nucleic acid molecule that down regulates expression of a VEGF receptor is a short interfering nucleic acid molecule.
- 25. The method of claim 21, wherein the interferon is type I interferon.
- 26. The method of claim 25, wherein said type I interferon and the compound are administered simultaneously.
- 27. The method of claim 25, wherein said type I interferon and the compound are administered separately.
- 28. The method of claim 25, wherein said type I interferon is selected from the group consisiting of interferon alpha, interferon beta, consensus interferon, polyethylene glycol interferon, polyethylene glycol interferon alpha 2a, polyethylene glycol interferon alpha 2b, and polyethylene glycol consensus interferon.
- 29. The method of claim 21, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, colorectal cancer, and melanoma.
- 30. The method of claim 21, wherein said administration is in the presence of a delivery reagent.
- 31. The method of claim 30, wherein said delivery reagent is a lipid, cationic lipid, phospholipid, or liposome.
Priority Claims (2)
Number |
Date |
Country |
Kind |
PCT/US96/17480 |
Oct 1996 |
WO |
|
PCT/US02/17674 |
May 2002 |
WO |
|
Parent Case Info
[0001] This patent application is a continuation-in-part of Pavco et al., U.S. Ser. No. 10/138,674, filed May 3, 2002, entitled “Enzymatic Nucleic Acid-Mediated Treatment of Ocular Diseases or Conditions Related to Levels of Vascular Endothelial Growth Factor Receptor (VEGF-R)” which is a continuation-in-part of Pavco et al., U.S. Ser. No. 09/870,161, filed May 29, 2001, which is a continuation-in-part of Pavco et al., U.S. Ser. No. 09/708,690, filed Nov. 7, 2000, which is a continuation-in-part of Pavco et al., U.S. Ser. No. 09/371,722, filed Aug. 10, 1999, which is a continuation-in-part of Pavco et al., U.S. Ser. No. 08/584,040, filed Jan. 11, 1996, which claims the benefit of Pavco et al., U.S. S No. 60/005,974, filed on Oct. 26, 1995, all which are entitled “Method and Reagent for Treatment of Diseases or Conditions Related To Levels of Vascular Endothelial Growth Factor Receptor”. Each of these applications is hereby incorporated by reference herein in its entirety including the drawings and tables.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60005974 |
Oct 1995 |
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
10138674 |
May 2002 |
US |
Child |
10287949 |
Nov 2002 |
US |
Parent |
09870161 |
May 2001 |
US |
Child |
10138674 |
May 2002 |
US |
Parent |
09708690 |
Nov 2000 |
US |
Child |
09870161 |
May 2001 |
US |
Parent |
09371722 |
Aug 1999 |
US |
Child |
09708690 |
Nov 2000 |
US |
Parent |
08584040 |
Jan 1996 |
US |
Child |
09371722 |
Aug 1999 |
US |